




RealRate

PHARMACEUTICAL 2015

Supernus Pharmaceuticals INC
Rank 134 of 274



The relative strengths and weaknesses of Supernus Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Supernus Pharmaceuticals INC compared to the market average is the variable Comprehensive Net Income, increasing the Economic Capital Ratio by 83% points. The greatest weakness of Supernus Pharmaceuticals INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 64% points.

The company's Economic Capital Ratio, given in the ranking table, is 283%, being 30% points above the market average of 254%.

Input Variable	Value in 1000 USD
Assets, Current	108,892
Cost of Goods Sold	0
Intangible Assets	5,434
Liabilities, Current	27,493
Liabilities, Non-Current	3,876
Other Assets	20,734
Other Compr. Net Income	-154
Other Expenses	5,758
Other Liabilities	34,785
Other Net Income	-4,359
Other Revenues	122,045
Property and Equipment	2,448
Research and Development	19,586
Selling, General and Administrative Expense	72,471

Output Variable	Value in 1000 USD
Assets	137,508
Liabilities	66,154
Expenses	97,815
Revenues	122,045
Stockholders Equity	71,354
Net Income	19,871
Comprehensive Net Income	19,794
BaseVar	214,018
ECR before LimitedLiability	172%
Economic Capital Ratio	283%